Avid Bioservices Inc (CDMO)

[goodJohnhunting]

With Bavituximab or BetaBodies one circumvents all that and simply bind PdSer (the LIGAND alike concept in PS world that binds PS-R the PS receptors).

BetaBodies don't rely on binding domains (b2gp1). However, would this circumventing create a paradox for attachment?

It appears obvious that eliminating binding traffic is paramount to success. In theory, statins would be synergistic in this regard, I/O combo's not so much, IMO.

I'm confident that this will eventually be tested. In the least, something similar to statin.

All the best,
John